Medical Condition News

RSS

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative medicines for eye disease, vascular disease and cancer, today announces results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME).

6 Oct 2009

Absence of certain proteins for proper cell duplication can lead to cancer

A Purdue University researcher has discovered that the absence of certain proteins needed for proper cell duplication can lead to cancer.

6 Oct 2009

Scientists identify new interference method to target cancer cells

Professor Jo Milner and Dr Shafiq Ahmed, from the YCR P53 Research Unit in the Department of Biology, used a process called RNA interference to target the JNK2 gene in both cancer and healthy cells. The cancer cells died but the healthy cells were unaffected.

6 Oct 2009

Sit-and-reach test to gauge age-related arterial stiffness

How far you can reach beyond your toes from a sitting position - normally used to define the flexibility of a person's body - may be an indicator of how stiff your arteries are.

6 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

Gilbert Hospital to provide renal dialysis services

There is a growing need for renal care, specifically, dialysis and proportionally, that growth is right here in the Valley" said David Wanger, the hospital's chief executive officer.

6 Oct 2009

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.

6 Oct 2009

Group Health Research Institute to receive federal stimulus funds from ARRA

Group Health Research Institute, formerly Group Health Center for Health Studies, will receive more than $15 million in federal stimulus funding from ARRA, the American Recovery and Reinvestment Act of 2009.

6 Oct 2009

Depression leads to elevated inflammatory proteins in the human body: Study

To help solve this long standing chicken and egg conundrum, researchers led by Jesse Stewart, Ph.D., assistant professor of psychology at Indiana University-Purdue University Indianapolis asked two critical questions. Does depression lead to elevated inflammatory proteins in the human body? Or does an increase in these proteins lead to depression? They found that the answer to the first question appears to be "yes," and the answer to the second question may be "no" among healthy adults.

6 Oct 2009

Pico-Tesla commences Phase III clinical trial its Resonator system for treating Parkinson’s disease

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has commenced a Phase III clinical trial of its patented Resonator™ system that facilitates the Company’s proprietary magnetic (Magneceutical™) therapy for treating Parkinson’s disease patients.

6 Oct 2009

General Mills launches Healthy Weight Commitment Foundation to address obesity

Reinforcing General Mills’ on-going commitment to helping Americans achieve a healthy weight through energy balance, the company joined retailers, non-government organizations and peer food and beverage manufacturers today to launch the Healthy Weight Commitment Foundation (HWCF).

6 Oct 2009

Drivers with Parkinson's disease at greater risk of crashes on foggy days

Drivers with mild to moderate Parkinson's disease may be at higher risk of crashes on foggy days and other times of low visibility. The research, involving a driving simulation test, is published in the October 6, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

6 Oct 2009

New journal on cancer biology and genetics

SAGE announces Genes & Cancer, a monthly journal edited by Dr. Prem Reddy, founder and previous Editor-in-Chief of the prestigious and highly-ranked Oncogene.

6 Oct 2009

Butler Hospital leads clinical study for effectiveness and safety of DBS for OCD

Butler Hospital in Providence, R.I., is leading a clinical study evaluating the effectiveness and safety of deep brain stimulation (DBS) for severe obsessive-compulsive disorder (OCD).

6 Oct 2009

ResMed announces acquisition of Laboratoires Narval

ResMed Inc. (NYSE: RMD), a leading developer, manufacturer and distributor of sleep and respiratory medical equipment, announced today that it has acquired Laboratoires Narval. Based in France, Laboratoires Narval manufactures and distributes the Narval O.R.M.(TM), an innovative mandibular repositioning device (MRD) that offers a solution to patients for snoring and obstructive sleep apnea (OSA), especially for those with mild OSA.

From ResMed Corp 6 Oct 2009

Campbell Soup's initiative to help reduce obesity

Campbell Soup Company is proud to team up with fellow members of the food and beverage industry, its retail customers and non-governmental organizations as part of the Healthy Weight Commitment Foundation to help reduce obesity by 2015.

6 Oct 2009

Eat strawberries to improve cholesterol levels

According to a new study published in the October 2009 issue of Nutrition Journal, women with metabolic syndrome had reduced total cholesterol levels - including LDL - after a brief period of daily consumption of a strawberry-based beverage.

6 Oct 2009

$16 million federal stimulus funds for cancer research projects

Researchers at Fred Hutchinson Cancer Research Center, Group Health Research Institute and the University of Washington schools of Public Health and Pharmacy have been selected to lead four projects backed by approximately $16 million in federal stimulus funding for comparative-effectiveness research in cancer.

6 Oct 2009

Pomegranate juice beneficial for patients with elevated cardiovascular disease risk factors: Study

According to a clinical study released in The American Journal of Cardiology, a daily serving of POM Wonderful 100% Pomegranate Juice may decrease the progression of arterial plaque in patients with elevated cardiovascular disease risk factors. The study was intended to see if POM Wonderful 100% Pomegranate Juice may slow the progression of intima-media thickness of the carotid artery (CIMT) in patients with moderate coronary heart disease risk.

6 Oct 2009

Guided Therapeutics awarded $2.5M NCI grant for marketing LightTouch technology

Guided Therapeutics, Inc. today announced that it was awarded a $2.5 million matching grant by the National Cancer Institute (NCI) to bring to market and expand the array features for its LightTouch™ non-invasive cervical cancer detection technology. The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.

6 Oct 2009